Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients



Status:Completed
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 74
Updated:4/21/2016
Start Date:June 2013
End Date:September 2014

Use our guide to learn which trials are right for you!

A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease

The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as
assessed by MRI and to assess its safety and tolerability profile in subjects with
non-alcoholic fatty liver disease (NAFLD).


Inclusion Criteria:

- History of liver steatosis during the preceding 24 months

- History of fasting TGs > 200 mg/dL (confirmed at screening).

- Liver fat ≥ 10% as determined by the central MRI laboratory.

- Subjects on the following medications can be included if these medications are
medically necessary, cannot be stopped and the investigator feels their dose will
remain stable for the duration of the double-blind treatment period:

1. Stable dose of anti-diabetic medications (metformin and/or sulfonylureas) for at
least 8 weeks prior to screening.

2. Stable doses of beta-blockers and thiazide diuretics for at least 8 weeks prior
to screening.

3. Stable doses of fibrates, statins, niacin, ezetimibe for at least 8 weeks prior
to screening.

4. Stable dose of vitamin E in patients taking >200 IU/day for at least 6 months
prior to screening.

Exclusion Criteria:

- Treatment with omega-3-acid ethyl esters or omega-3-polyunsaturated fatty acid
(PUFA)-containing supplements > 200 mg per day within 8 weeks of screening.

- Treatment with antiretrovirals, tamoxifen, methotrexate, cyclophosphamide,
isotretinoin, bile acid binding resins or pharmacologic doses of oral glucocorticoids
(≥10 mg of prednisone per day or equivalent) within 8 weeks of screening.

- ALT or AST > 250 IU/L at the time of screening.

- History/current evidence of heavy alcohol use or alcoholism (> 21 drinks per week in
men and > 14 drinks per week in women) over a 2-year period prior to screening.

- Presence of chronic liver disease, such as chronic hepatitis B and/or C, alcoholic
liver disease, hemochromatosis, Wilson's disease, known cirrhosis.

- Platelet count <150,000 at screening.

- BMI >45 Kg/m2.

Other protocol defined inclusion/exclusion criteria may apply
We found this trial at
12
sites
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Gainesville, Florida 32608
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Honolulu, Hawaii 96813
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mobile, Alabama 36693
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Plano, Texas 75024
?
mi
from
Plano, TX
Click here to add this to my saved trials
Richmond, Virginia 23249
?
mi
from
Richmond, VA
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Tamarac, Florida 33321
?
mi
from
Tamarac, FL
Click here to add this to my saved trials
Tupelo, Mississippi 38801
?
mi
from
Tupelo, MS
Click here to add this to my saved trials